The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Heartware International's revenues will expand 30.2% and EPS will remain in the red.
The average estimate for revenue is $28.7 million. On the bottom line, the average EPS estimate is -$1.64.
Last quarter, Heartware International booked revenue of $22.8 million. GAAP reported sales were 7.1% higher than the prior-year quarter's $21.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$1.75. GAAP EPS were -$0.05 for Q3 against -$0.03 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.2%, 1,090 basis points worse than the prior-year quarter. Operating margin was -96.7%, 4,950 basis points worse than the prior-year quarter. Net margin was -109.3%, 4,390 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $106.7 million. The average EPS estimate is -$6.34.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 29 members out of 47 rating the stock outperform, and 18 members rating it underperform. Among 16 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), nine give Heartware International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Heartware International is outperform, with an average price target of $96.86.
Is Heartware International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Heartware International to My Watchlist.